Frisius MC

Futó vizsgálatok

• Még nem toboroz

  Addition of ritonavir to ibrutinib treatment in patients with chronic leukemia and certain types of lymphoma

  2026-526101-15-00· 2. fázis· Forrás

• Toboroz

  Albuminuria Reduction Trial and Investigation with Survodutide Treatment in CKD (ARTIST-CKD)

  2025-525068-13-00· 2. fázis· Forrás

• Toboroz

  Phase 3 Study of Investigator Choice of Chemotherapy with or without Zoldonrasib as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma

  2025-524928-21-00· 3. fázis· Forrás

• Még nem toboroz

  Tapering optimisation with placebo-based mechanisms in rheumatoid arthritis: the TOP-RA trial

  2025-524593-42-00· 4. fázis· Forrás

• Még nem toboroz

  Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma With Pirtobrutinib in Combination With Epcoritamab if the Disease Comes Back After Previous Treatment.

  NCT07860775· 2. fázis· Forrás

• Toboroz

  HO182 CLL: Treatment of patients with chronic lymphocytic leukemia (CLL) with 6 cycles of rituximab in combination with 6 or 26 cycles of venetoclax upon recurrence of the disease after previous treatment

  2025-524283-38-00· 3. fázis· Forrás

• Toboroz

  A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF

  NCT07761117· 3. fázis· Forrás

• Toboroz

  ReVeRA-301: Etripamil in Atrial Fibrillation Phase 3

  NCT06716021· 3. fázis· Forrás

• Toboroz

  Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden

  NCT07621809· 3. fázis· Forrás

• Még nem toboroz

  HOVON 168:Study on epcoritamab in frail patients with diffuse large B-Cell lymphoma (DLBCL) who have not been treated before

  2025-524230-25-00· 2. fázis· Forrás

• Toboroz

  A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)

  NCT07513376· 3. fázis· Forrás

• Még nem toboroz

  Pembrolizumab Adjuvant in Patients With Early-stage Triple Negative Breast Cancer With Residual Disease After Neoadjuvant Pembrolizumab Plus Chemotherapy

  NCT07486687· 3. fázis· Forrás

• Még nem toboroz

  Effectiveness and Safety of Uptitration of Guideline Directed MEdical Therapy in Heart Failure With Reduced Ejection Fraction With Limited Kidney Function Assessments

  NCT07275437· Forrás

• Toboroz

  Neoadjuvant FOLFOXIRI and Chemoradiotherapy versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy, followed by Surgery or a Watch-and-Wait Approach in High Risk Locally Advanced Rectal Cancer

  NCT07472868· 3. fázis· Forrás

• Toboroz

  Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)

  NCT07223814· 3. fázis· Forrás

• Toboroz

  Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease

  NCT07404865· 3. fázis· Forrás

• Toboroz

  A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)

  NCT07241390· 3. fázis· Forrás

• Toboroz

  Clinical Phase 2 Trial of AP31969 Versus Placebo for Rhythm Control of Atrial Fibrillation

  NCT07267949· 2. fázis· Forrás

• Toboroz

  ctDNA-Based Adjuvant Chemotherapy for High-Risk Rectal Cancer

  NCT07188025· 3. fázis· Forrás

• Fut, nem toboroz

  Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and Overweight or Obesity (MARITIME-CV)

  2024-516652-18-00· 3. fázis· Forrás

• Toboroz

  Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF)

  2024-516654-22-00· 3. fázis· Forrás

• Toboroz

  The BRidge Towards Implementation of Blood-based Biomarkers to Enable Early and Accurate Diagnosis of Alzheimer's Disease

  NCT07680335· Forrás

• Toboroz

  Total Neoadjuvant Therapy for Lymph Node-positive Adenocarcinoma of the OESophagus and Oesophagogastric Junction

  NCT06161818· 2. fázis· Forrás

• Toboroz

  Prospective Data Collection Initiative on Thoracic Malignancies

  NCT06996249· Forrás

• Toboroz

  This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

  NCT06758401· 3. fázis· Forrás

• Toboroz

  [18F]F-FAPI PET/CT and Laparoscopy in Staging Advanced Gastric Cancer

  NCT07018661· 2/3. fázis· Forrás

• Toboroz

  Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation

  NCT06959095· 3. fázis· Forrás

• Toboroz

  Trial of Trastuzumab Deruxtecan (Enhertu®) Plus Chemotherapy Plus or Minus Pembrolizumab versus Chemotherapy Plus Trastuzumab Plus or Minus Pembrolizumab in First-line Metastatic HER2-positive Gastric or GEJ Cancer

  2024-513122-27-00· 3. fázis· Forrás

• Toboroz

  A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer

  NCT06901531· 3. fázis· Forrás

• Toboroz

  StAtins in Frail oldEr patients with ischemic Stroke or Transient ischemic attack – The Randomized Controlled Trial

  2024-517343-31-00· 4. fázis· Forrás

• Toboroz

  DAROTAXEL

  2024-516939-28-00· 2. fázis· Forrás

• Toboroz

  A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

  NCT06629779· 3. fázis· Forrás

• Fut, nem toboroz

  A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).

  NCT06551324· 3. fázis· Forrás

• Fut, nem toboroz

  Dose tapering and Early Discontinuation to InCreAse cosT-effictIveness Of immunotherapy for Non-small cell lung carcinoma trial number 1 (NVALT-30 - Dedication-1)

  NCT04909684· 3. fázis· Forrás

• Toboroz

  FeAsiBility of a Treatment Free Interval in Newly Diagnosed MM Patients Treated With Daratumumab-lenalidomide-dexamethasone (HOVON174MM)

  NCT06187441· 3. fázis· Forrás

• Toboroz

  Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLL

  NCT05791409· 1/2. fázis· Forrás

• Toboroz

  A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

  NCT06119581· 3. fázis· Forrás

• Toboroz

  REtreatment With VEnetoclax and Acalabrutinib After Venetoclax Limited Duration (REVEAL)

  NCT04523428· 2. fázis· Forrás

• Fut, nem toboroz

  A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy

  NCT04027309· 3. fázis· Forrás

• Fut, nem toboroz

  A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy

  NCT03839771· 3. fázis· Forrás

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

• Krónikus limfoid leukémia (CLL)5 toboroz
• Tüdőrák4 toboroz
• Gyomor- és nyelőcsőrák3 toboroz
• Szívelégtelenség3 toboroz
• Krónikus vesebetegség2 toboroz
• Pitvarfibrilláció2 toboroz
• Sjögren-szindróma2 toboroz
• Stroke (szélütés)2 toboroz
• Vastagbélrák2 toboroz
• Akut mieloid leukémia (AML)1 toboroz
• Alzheimer-kór1 toboroz
• Diffúz nagy B-sejtes limfóma (DLBCL)1 toboroz
• Elhízás1 toboroz
• Hasnyálmirigyrák1 toboroz
• Köpenysejtes limfóma1 toboroz
• Krónikus obstruktív tüdőbetegség (COPD)1 toboroz
• Mezotelióma1 toboroz
• Mielóma multiplex1 toboroz
• Prosztatarák1 toboroz
• Rheumatoid arthritis1 toboroz
• Tripla negatív emlőrák1 toboroz

Kutatók

Ide még nem kötődik kutató.

Lezárt vizsgálatok

• Lezárult

  A Study With CIT-013 in RA Patients

  NCT06567470· 2. fázis· Forrás

• Fut, nem toboroz

  A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer

  NCT06614192· 2. fázis· Forrás

• Fut, nem toboroz

  Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.

  NCT05445843· 2. fázis· Forrás

• Fut, nem toboroz

  A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer

  NCT05565378· 2. fázis· Forrás